NVO vs. PFE
NVO (Novo Nordisk A/S) and PFE (Pfizer Inc.) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, NVO returned 7.06%/yr vs 2.17%/yr for PFE. At a 0.24 correlation, their price movements are largely independent.
Performance
NVO vs. PFE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a -10.58% return, which is significantly lower than PFE's 8.62% return. Over the past 10 years, NVO has outperformed PFE with an annualized return of 7.06%, while PFE has yielded a comparatively lower 2.17% annualized return.
NVO
- 1D
- 2.69%
- 1M
- -6.47%
- YTD
- -10.58%
- 6M
- -9.53%
- 1Y
- -41.56%
- 3Y*
- -15.73%
- 5Y*
- 2.96%
- 10Y*
- 7.06%
PFE
- 1D
- 2.23%
- 1M
- 1.16%
- YTD
- 8.62%
- 6M
- 4.84%
- 1Y
- 14.37%
- 3Y*
- -7.54%
- 5Y*
- -3.38%
- 10Y*
- 2.17%
NVO vs. PFE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -10.58% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
PFE Pfizer Inc. | 8.62% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
Correlation
The correlation between NVO and PFE is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.30 |
Correlation (All Time) Calculated using the full available price history since Jan 4, 1982 | 0.24 |
The correlation between NVO and PFE shifts across timeframes, from 0.24 (3 years) to 0.34 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
NVO:
$195.56B
PFE:
$149.98B
NVO:
DKK 27.42
PFE:
$1.31
NVO:
10.37
PFE:
19.95
NVO:
0.44
PFE:
0.36
NVO:
3.86
PFE:
2.36
NVO:
6.23
PFE:
1.66
NVO:
DKK 327.80B
PFE:
$63.32B
NVO:
DKK 268.30B
PFE:
$43.91B
NVO:
DKK 181.54B
PFE:
$16.94B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. PFE — Risk / Return Rank
NVO
PFE
NVO vs. PFE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVO | PFE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.41 | ||
| Sortino ratioReturn per unit of downside risk | -2.04 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.13 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 1.26 | -2.02 |
| Martin ratioReturn relative to average drawdown | -1.11 | 2.54 | -3.64 |
Loading charts...
Drawdowns
NVO vs. PFE - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, which is greater than PFE's maximum drawdown of -69.24%. Use the drawdown chart below to compare losses from any high point for NVO and PFE.
Loading charts...
Drawdown Indicators
| NVO | PFE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -69.24% | -5.46% |
Max Drawdown (1Y)Largest decline over 1 year | -55.03% | -11.47% | -43.56% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -40.75% | -33.95% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -58.96% | -15.74% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | -58.96% | -15.74% |
Current DrawdownCurrent decline from peak | -68.06% | -45.76% | -22.30% |
Average DrawdownAverage peak-to-trough decline | -17.78% | -22.90% | +5.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.52% | 5.68% | +31.84% |
Volatility
NVO vs. PFE - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 10.69% compared to Pfizer Inc. (PFE) at 5.08%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | PFE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.69% | 5.08% | +5.61% |
Volatility (6M)Calculated over the trailing 6-month period | 38.46% | 14.72% | +23.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.88% | 23.85% | +28.03% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.34% | 25.49% | +12.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 23.89% | +8.67% |
Dividends
NVO vs. PFE - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.10%, less than PFE's 6.57% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 4.10% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
PFE Pfizer Inc. | 6.57% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
NVO vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. PFE - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
Frequently Asked Questions
NVO and PFE have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVO has higher volatility (10.69%) compared to PFE (5.08%). In terms of maximum drawdown, NVO dropped -74.70% vs PFE's -69.24%.
PFE currently has the higher Sharpe Ratio (0.61 vs -0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and PFE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer